CSE1L as a prognostic biomarker associated with pan cancer immune infiltration and drug sensitivity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CSE1L as a prognostic biomarker associated with pan cancer immune infiltration and drug sensitivity

Published:2024-05-23 Issue:9 Volume:20 Page:1113-1125
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Li Haiyang¹,Wang Lingwa¹,Ruan Zhaohui²,Li Xiaoyan³,Yang Yifan¹,Fang Jugao¹,Wang Ru¹

Affiliation:

1. Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China

2. Department of Major Emerging Infectious Diseases, Changping Laboratory, Beijing, China

3. Teaching and Research Section of Clinical Nursing, Xiangya Hospital of Central South University, Changsha, China

Funder

Capital Health Research and Development of Special Fund

National Natural Science Foundation of China

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2024.2356747

Reference44 articles.

1. PD-L1 as a biomarker of response to immune-checkpoint inhibitors

2. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

3. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

4. Cancer immunotherapy using checkpoint blockade

5. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP